Cancer Treatment Reviews
Volume 30, Issue 6 , Pages 577-582 , October 2004

Initial high dose chemotherapy plus autologous stem cell support improves survival outcomes compared with a standard CHOP regimen in people with higher intermediate risk aggressive lymphoma: Abstracted from: Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004;350:1287–95.

References 

  1. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002;346:235–242
  2. Pfreundschuh M, Truemper L, Kloess M, et al. 2-weekly or 3-weekly CHOP Chemotherapy with or without etoposide for the treatment of young patients with good prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104:634–641
  3. The International Non-Hodgkin’s Lymphoma Prognosis Factors Project. A predictive model for aggressive non-hodgkin’s lymphoma. the international non-Hodgkin’s lymphoma prognostic factors project. N Engl J Med 1993;329:987–94
  4. Strehl J, Mey U, Glasmacher A, et al. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin’s lymphoma: a meta-analysis. Haematologica. 2003;88:1304–1315
  5. Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protocol. A groupe d’Etude des lymphomes de l’Adulte study. J. Clin. Oncol. 2000;18:3025–3030
  6. Santini G, Salvagno L, Leoni P, et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin’s lymphoma: results of a prospective randomized trial by the non-Hodgkin’s Lymphoma Cooperative Study Group. J. Clin. Oncol. 1998;16:2796–2802
  7. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N. Engl. J. Med. 1993;328:1002–1006
  8. Kaiser U, Uebelacker I, Abel U, et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for aggressive lymphoma. J. Clin. Oncol. 2002;20:4413–4419

☆ Sources of funding: Supported in part by grants from Schering Laboratories of France.

☆☆ For Correspondence: Noel Milpie, University Hospital of Nantes, Nantes, France. noel.milpied@chu-nantes.fr.

☆☆☆ Abstract provided by Bazian Ltd., London.

PII: S0305-7372(04)00120-3

doi: 10.1016/j.ctrv.2004.06.004

Cancer Treatment Reviews
Volume 30, Issue 6 , Pages 577-582 , October 2004

Article Tools